Patent: 10,046,056
✉ Email this page to a colleague
Summary for Patent: 10,046,056
Title: | Glycotargeting therapeutics |
Abstract: | Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein. |
Inventor(s): | Hubbell; Jeffrey A. (Chicago, IL), Wilson; David Scott (Lausanne, CH) |
Assignee: | Ecole Polytechnique Federale de Lausanne (EPFL) (Lausanne, CH) |
Application Number: | 15/185,564 |
Patent Claims: | see list of patent claims |
Details for Patent 10,046,056
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2034-02-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |